Abbott Laboratories’s (NYSE:ABT) Q3 2026 earnings results: revenue in line with expectations
Abbott Laboratories’s (NYSE:ABT) Q3 2026 earnings results: revenue in line with expectations TradingView
Covered in this story
Analyst targets on Abbott Laboratories
- Rothschild & Co Redburn: $97.5 → $127 by Oct 2027 via Investing.com
- TD Cowen: $117 → $135 by Aug 2027 · Buy via Investing.com India
- UBS: $107 → $125 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 49 stories mentioning Abbott Laboratories, the earliest published 23 May 2026.
Summary aggregated from TradingView's public RSS feed. The full reporting belongs to TradingView — please read it on their site.